Table 3.
Group | No. of Participants | Age of Ascertainment (years) |
Follow-Up (years) |
No. of Participants Diagnosed With Cancer | Age at Diagnosis (years) |
Hazard Ratio | 95% CI | |||
---|---|---|---|---|---|---|---|---|---|---|
Mean | Range | Mean | Range | Mean | Range | |||||
BRCA1 | ||||||||||
Non-CJM | 1,087 | 37.9 | 2.2-88.6 | 5.7 | 0.0-33.3 | 171 | 42.3 | 22.2-72.7 | Ref | |
185delAG | 312 | 41.3 | 10.2-90.4 | 4.7 | 0.0-33.1 | 51 | 43.5 | 27.6-73.2 | 1.23 | 0.87 to 1.73 |
5382insC | 124 | 41.4 | 12.3-87.6 | 4.6 | 0.0-18.1 | 27 | 43.2 | 24.9-62.7 | 1.53 | 0.96 to 2.45 |
BRCA2 | ||||||||||
Non-CJM | 663 | 40.5 | 2.0-89.3 | 4.6 | 0.0-28.3 | 134 | 45.9 | 19.1-80.1 | Ref | |
6174delT | 176 | 45.4 | 17.7-79.1 | 4.1 | 0.0-16.2 | 13 | 48.1 | 32.5-70.5 | 0.35 | 0.18 to 0.69 |
Non-Jewish | 1,874 | 39.1 | 2.0-89.3 | 5.2 | 0.0-33.3 | 334 | 43.7 | 19.1-80.1 | Ref | |
Jewish | 488 | 42.7 | 10.2-90.4 | 4.7 | 0.0-33.1 | 62 | 45.2 | 27.6-73.2 | 0.76 | 0.56 to 1.01 |
RRSO | ||||||||||
No | 1,599 | 38.2 | 2.0-90.4 | 4.5 | 0.0-28.3 | 317 | 42.9 | 19.1-80.1 | Ref | |
Yes | 763 | 43.2 | 15.4-83.7 | 6.5 | 0.0-33.3 | 79 | 47.9 | 33.3-72.7 | 0.62 | 0.47 to 0.83 |
Abbreviations: CJM, common Jewish mutation; Ref, reference; RRSO, risk-reducing salpingo-oophorectomy.